Who founded Glyscend?

Glyscend was founded by Ashish Nimgaonkar.

Who are Glyscend's investors?

Glyscend's investors include Brandon BioCatalyst.

How much funding has Glyscend raised?

Glyscend has disclosed $4.8M raised across 1 round.

Where is Glyscend headquartered?

Glyscend is headquartered in Baltimore, US.

Glyscend

Baltimore, US · Delaware corporation · 1 known investors

glyscend.com ↗

Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. Its approach originated from research on how certain bariatric surgeries improve glucose and metabolic regulation and produce sustained weight loss.

BiotechDeep TechDigital HealthHealthtechLongevity

Founders & leadership

Ashish NimgaonkarFounder

Dennis McWilliamsNamed on SEC filing

Casey CunninghamNamed on SEC filing

Leighton ReadNamed on SEC filing

Bob SohNamed on SEC filing

Investors · 1

Brandon BioCatalystMelbourne

Competitors · 2

by search overlap

Novo Nordisk5 shared keywordsNovo Nordisk is a pharmaceutical company; this page is an investor relations section listing upcoming financial calendar events and quarterly results announcements.

Clinicaltrialsarena4 shared keywordsClinical Trials Arena is an online news and information publication covering the clinical trials industry, including trends, regulatory developments, and industry events. It serves professionals working in pharmaceutical and clinical research.

Companies competing with Glyscend for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

$4.8M disclosed across 1 round · 2020

▶$4.8MraisedFeb 2020 · 10 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Dennis McWilliamsDirector
Casey CunninghamDirector
Ashish NimgaonkarExecutive Officer, Director
Leighton ReadDirector
Bob SohDirector

Offering amount: $20.9M
Amount sold: $4.8M
Minimum investment: $1
First sale: Feb 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Science Foundation	Phase II	2017	$500K
National Science Foundation	Phase ISTTR	2015	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Glyscend do?: Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. Its approach originated from research on how certain bariatric surgeries improve glucose and metabolic regulation and produce sustained weight loss.
Who founded Glyscend?: Glyscend was founded by Ashish Nimgaonkar.
Who are Glyscend's investors?: Glyscend's investors include Brandon BioCatalyst.
How much funding has Glyscend raised?: Glyscend has disclosed $4.8M raised across 1 round.
Where is Glyscend headquartered?: Glyscend is headquartered in Baltimore, US.